# HRK

## Overview
The HRK gene encodes the harakiri protein, a pro-apoptotic member of the Bcl-2 family, specifically classified within the BH3-only subfamily. This protein plays a pivotal role in the regulation of apoptosis, or programmed cell death, by interacting with anti-apoptotic proteins such as Bcl-2 and Bcl-xL through its BH3 domain. The harakiri protein is primarily localized to the mitochondria, where it contributes to the apoptotic cascade by facilitating the release of cytochrome c. Its expression is notably significant in the nervous system, where it regulates apoptosis in response to various stimuli, including nerve growth factor withdrawal. The HRK gene's involvement in apoptosis makes it a critical factor in maintaining cellular homeostasis and has implications in various diseases, including cancer and myositis, where its dysregulation can lead to pathological conditions (Coultas2007HrkDP5; Boehler2019Mitochondrial; Inohara1997harakiri).

## Structure
The HRK protein, also known as harakiri, is a pro-apoptotic member of the Bcl-2 family. It is characterized by a BH3 domain, which is essential for its interaction with anti-apoptotic proteins such as Bcl-2 and Bcl-xL, and is necessary for inducing apoptosis (Bernabeu2007Structure; Ham2012HRK). The protein is 91 amino acids long in humans and contains a carboxy terminal transmembrane domain rich in hydrophobic amino acids, allowing it to insert into the mitochondrial outer membrane and adopt a transmembrane alpha-helical structure (Bernabeu2007Structure; Ham2012HRK).

The C-terminal domain of HRK, corresponding to residues 65-91, is identified as a transmembrane segment with high interfaciality and aromatic residues typical of transmembrane regions (Bernabeu2007Structure). This domain adopts a predominantly α-helical structure, oriented nearly perpendicular to the membrane plane, which allows it to perturb membrane properties (Bernabeu2007Structure). HRK does not have a known quaternary structure, as it primarily interacts with other proteins rather than forming multimeric complexes (Ham2012HRK). The protein's apoptotic activity is regulated by the c-Jun N-terminal kinase pathway and requires Bax expression (Bernabeu2007Structure).

## Function
The HRK gene encodes a pro-apoptotic protein known as Harakiri, which is a member of the Bcl-2 family, specifically the BH3-only subfamily. This protein plays a crucial role in regulating apoptosis, or programmed cell death, by interacting with anti-apoptotic proteins such as Bcl-2 and Bcl-xL. The interaction occurs through the BH3 domain of Harakiri, which is essential for its function. This domain allows Harakiri to bind to Bcl-2 and Bcl-xL, antagonizing their survival-promoting effects and promoting apoptosis (Inohara1997harakiri).

In healthy human cells, HRK is involved in maintaining cellular homeostasis by regulating cell survival and death. It is primarily active in the mitochondria, where it contributes to the release of cytochrome c, a key step in the apoptotic cascade (Inohara1997harakiri). HRK expression is particularly prominent in the nervous system, where it is involved in apoptosis regulation in response to nerve growth factor withdrawal and other apoptotic stimuli (Coultas2007HrkDP5). The protein's activity is crucial for balancing neuronal production and death, particularly in regions like the hippocampus, which is involved in postnatal neurogenesis (Coultas2007HrkDP5).

## Clinical Significance
Alterations in the HRK gene are implicated in several diseases, primarily through its role in apoptosis. In myositis, a condition characterized by muscle inflammation and weakness, HRK-induced mitochondrial dysfunction is linked to poor plasma membrane repair, leading to inflammation. This is mediated by toll-like receptor 7 (TLR7), which is upregulated in myositis patients. A feedback loop involving HRK and TLR7 may contribute to sustained inflammation in this condition (Boehler2019Mitochondrial).

In colorectal cancer (CRC), HRK acts as a tumor suppressor. Its expression is lower in cancerous tissues, correlating with increased cell proliferation, invasion, and migration, as well as reduced apoptosis. HRK influences the PI3K/AKT/mTOR signaling pathway, where its low expression leads to pathway activation, promoting cancer cell survival and growth. Overexpression of HRK suppresses this pathway, reducing CRC cell growth (Wang2022HRK).

In prostate cancer, HRK expression is often lost due to promoter methylation and loss of heterozygosity, contributing to tumor progression by reducing apoptosis. This inactivation is associated with higher-grade tumors and a decreased apoptotic index (Higuchi2007HRK).

## Interactions
The HRK protein, encoded by the harakiri gene, is a pro-apoptotic member of the Bcl-2 family that interacts with several proteins to regulate apoptosis. HRK specifically binds to the anti-apoptotic proteins Bcl-2 and Bcl-xL through its BH3 domain, a critical region for these interactions. This binding is essential for HRK's ability to induce apoptosis, as deletion of the BH3 domain significantly reduces its apoptotic activity (Inohara1997harakiri). The interaction with Bcl-2 and Bcl-xL suggests that HRK may function by antagonizing their anti-apoptotic effects, promoting cell death (Inohara1997harakiri).

In addition to its interactions with Bcl-2 family proteins, HRK also interacts with the mitochondrial pore-forming protein p32. This interaction is independent of the BH3 domain and involves the post-BH3 region of HRK. The binding of HRK to p32 is crucial for its pro-apoptotic activity, as demonstrated by the protective effect of p32 knockdown against HRK-induced apoptosis (Sunayama2004Physical). The interaction with p32 highlights a unique mechanism by which HRK can induce apoptosis, distinct from its interactions with Bcl-2 and Bcl-xL (Sunayama2004Physical).


## References


[1. (Coultas2007HrkDP5) Leigh Coultas, Susanna Terzano, Tim Thomas, Anne Voss, Kate Reid, Edouard G. Stanley, Clare L. Scott, Philippe Bouillet, Perry Bartlett, Jonathan Ham, Jerry M. Adams, and Andreas Strasser. Hrk/dp5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis. Journal of Cell Science, 120(12):2044–2052, June 2007. URL: http://dx.doi.org/10.1242/jcs.002063, doi:10.1242/jcs.002063. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.002063)

[2. (Higuchi2007HRK) Tomonori Higuchi, Mitsutoshi Nakamura, Keiji Shimada, Eiwa Ishida, Kazuya Hirao, and Noboru Konishi. Hrk inactivation associated with promoter methylation and loh in prostate cancer. The Prostate, 68(1):105–113, November 2007. URL: http://dx.doi.org/10.1002/pros.20600, doi:10.1002/pros.20600. This article has 23 citations.](https://doi.org/10.1002/pros.20600)

[3. (Ham2012HRK) J Ham. Hrk (harakiri, bcl2 interacting protein (contains only bh3 domain)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, March 2012. URL: http://dx.doi.org/10.4267/2042/46085, doi:10.4267/2042/46085. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4267/2042/46085)

[4. (Sunayama2004Physical) J Sunayama, Y Ando, N Itoh, A Tomiyama, K Sakurada, A Sugiyama, D Kang, F Tashiro, Y Gotoh, Y Kuchino, and C Kitanaka. Physical and functional interaction between bh3-only protein hrk and mitochondrial pore-forming protein p32. Cell Death &amp; Differentiation, 11(7):771–781, March 2004. URL: http://dx.doi.org/10.1038/sj.cdd.4401418, doi:10.1038/sj.cdd.4401418. This article has 64 citations.](https://doi.org/10.1038/sj.cdd.4401418)

[5. (Inohara1997harakiri) N. Inohara. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins bcl-2 and bcl-xl. The EMBO Journal, 16(7):1686–1694, April 1997. URL: http://dx.doi.org/10.1093/emboj/16.7.1686, doi:10.1093/emboj/16.7.1686. This article has 289 citations.](https://doi.org/10.1093/emboj/16.7.1686)

[6. (Bernabeu2007Structure) Angela Bernabeu, Jaime Guillén, Ana J. Pérez-Berná, Miguel R. Moreno, and José Villalaín. Structure of the c-terminal domain of the pro-apoptotic protein hrk and its interaction with model membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1768(6):1659–1670, June 2007. URL: http://dx.doi.org/10.1016/j.bbamem.2007.02.023, doi:10.1016/j.bbamem.2007.02.023. This article has 27 citations.](https://doi.org/10.1016/j.bbamem.2007.02.023)

[7. (Wang2022HRK) Haowei Wang, Yujia Chen, Qinzi Yuan, Lixia Chen, Peiling Dai, and Xuenong Li. Hrk inhibits colorectal cancer cells proliferation by suppressing the pi3k/akt/mtor pathway. Frontiers in Oncology, December 2022. URL: http://dx.doi.org/10.3389/fonc.2022.1053510, doi:10.3389/fonc.2022.1053510. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.1053510)

[8. (Boehler2019Mitochondrial) Jessica F Boehler, Adam Horn, James S Novak, Ning Li, Svetlana Ghimbovschi, Ingrid E Lundberg, Helene Alexanderson, Li Alemo Munters, Jyoti K Jaiswal, and Kanneboyina Nagaraju. Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. The Journal of Pathology, 249(2):215–226, July 2019. URL: http://dx.doi.org/10.1002/path.5309, doi:10.1002/path.5309. This article has 28 citations.](https://doi.org/10.1002/path.5309)